Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alfredo Gonzalez-Alcocer has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unscrambling the Role of Redox-Active Biometals in Dopaminergic Neuronal Death and Promising Metal Chelation-Based Therapy for Parkinson’s Disease

    by Alfredo Gonzalez-Alcocer, Ana Patricia Duarte-Jurado, Adolfo Soto-Dominguez, Maria de Jesus Loera-Arias, Eliud Enrique Villarreal-Silva, Odila Saucedo-Cardenas, Roberto Montes de Oca-Luna, Aracely Garcia-Garcia, Humberto Rodriguez-Rocha

    Biometals are all metal ions that are essential for all living organisms. About 40% of all enzymes with known structures require biometals to function correctly. The main target of damage by biometals is the central nervous system (CNS). Biometal dysregulation (metal deficiency or overload) is related to pathological processes. Chronic occupational and environmental exposure to biometals, including iron and copper, is related to an increased risk of developing Parkinson’s disease (PD). Indeed, biometals have been shown to induce a dopaminergic neuronal loss in the substantia nigra. Although the etiology of PD is still unknown, oxidative stress dysregulation, mitochondrial dysfunction, and inhibition of both the ubiquitin–proteasome system (UPS) and autophagy are related to dopaminergic neuronal death. Herein, we addressed the involvement of redox-active biometals, iron, and copper, as oxidative stress and neuronal death inducers, as well as the current metal chelation-based therapy in PD.


  • Peripheral tissular analysis of rapamycin’s effect as a neuroprotective agent in vivo

    by Alfredo Gonzalez-Alcocer, Yareth Gopar-Cuevas, Adolfo Soto-Dominguez, Maria de Jesus Loera- Arias, Odila Saucedo-Cardenas, Roberto Montes de Oca-Luna, Humberto Rodriguez-Rocha, Aracely Garcia-Garcia

    Rapamycin is the best-characterized autophagy inducer, which is related to its antiaging and neuroprotective effects. Although rapamycin is an FDA-approved drug for human use in organ transplantation and cancer therapy, its administration as an antiaging and neuroprotective agent is still controversial because of its immunosuppressive and reported side effects. Therefore, it is critical to determine whether the dose that exerts a neuroprotective effect, 35 times lower than that used as an immunosuppressant agent, harms peripheral organs. We validated the rapamycin neuroprotective dosage in a Parkinsonʼs disease (PD) model induced with paraquat. C57BL/6 J mice were treated with intraperitoneal (IP) rapamycin (1 mg/kg) three times per week, followed by paraquat (10 mg/kg) twice per week for 6 weeks, along with rapamycin on alternate days. Rapamycin significantly decreased dopaminergic neuronal loss induced by paraquat. Since rapamycin’s neuroprotective effect in a PD model was observed at 7 weeks of treatment; we evaluated its effect on the liver, kidney, pancreas, and spleen. In addition, we prolonged treatment with rapamycin for 14 weeks. Tissue sections were subjected to histochemical, immunodetection, and morphometric analysis. Chronic rapamycin administration does not affect bodyweight, survival, and liver or kidney morphology. Although the pancreas tissular architecture and cellular distribution in Langerhans islets are modified, they may be reversible. The spleen B lymphocyte and macrophage populations were decreased. Notably, the lymphocyte T population was not affected. Therefore, chronic administration of a rapamycin neuroprotective dose does not produce significant tissular alterations. Our findings support the therapeutic potential of rapamycin as a neuroprotective agent. Graphical abstract


  • Effect of methanolic extract of Mimosa malacophylla A.Gray in vero and HEK-293 cell lines, and in the morphology of kidney and bladder of rats with induced urolithiasis

    by Gloria A. Guillén-Meléndez, Adolfo Soto-Domínguez, María de Jesús Loera-Arias, Uziel Castillo-Velázquez, Sheila A. Villa-Cedillo, Edgar I. Piña-Mendoza, Eduardo Estrada-Castillón, Abelardo Chávez-Montes, Alfredo González-Alcocer, Eduardo M. Becerra-Verdín, et al.


  • Autophagy Stimulation Decreases Dopaminergic Neuronal Death Mediated by Oxidative Stress

    by Marcela J. Ramirez-Moreno, Ana P. Duarte-Jurado, Yareth Gopar-Cuevas, Alfredo Gonzalez-Alcocer, Maria J. Loera-Arias, Odila Saucedo-Cardenas, Roberto Montes de Oca-Luna, Humberto Rodriguez-Rocha, Aracely Garcia-Garcia

    The neurodegenerative process of Parkinson’s disease (PD) involves autophagy impairment and oxidative stress. Therefore, we wanted to determine whether stimulation of autophagy protects dopaminergic cell death induced by oxidative stress in a PD model. Since environmental exposure to herbicides increases the risk to develop PD, the experimental model was established using the herbicide paraquat, which induces autophagy disruption, oxidative stress, and cell death. Rapamycin-stimulated autophagy inhibited calpain-dependent and independent apoptosis induced by paraquat. Autophagy stimulation decreased oxidative stress and peroxiredoxins (PRXs) hyperoxidation induced by paraquat. Cells exposed to paraquat displayed abnormally large autophagosomes enclosing mitochondria, which correlates with an increase of p62, an essential mitophagy regulator. Interestingly, when autophagy was stimulated before paraquat treatment, autophagosome size and number were similar to that observed in control cells. Motor and cognitive function impairment induced by paraquat showed an improvement when preceded by autophagy stimulation. Importantly, dopaminergic neuronal death and microglial activation mediated by paraquat were significantly reduced by rapamycin-induced autophagy. Our results indicate that autophagy stimulation has a protective effect on dopaminergic neurons and may have a promising potential to prevent or delay PD progression.